INS and gastric cancer: Higher gastric cancer risk was found in the group of diabetic patients treated with sulfonylureas (SIR 1.31, 95% CI: 1.04–1.65) as well as insulin and other medications (SIR 1.16, 95% CI: 0.73–1.84), although the latter result was insignificant.